首页> 外文期刊>ACS Omega >Identifying the Responses from the Estrogen Receptor-Expressed MCF7 Cells Treated in Anticancer Drugs of Different Modes of Action Using Live-Cell FTIR Spectroscopy
【24h】

Identifying the Responses from the Estrogen Receptor-Expressed MCF7 Cells Treated in Anticancer Drugs of Different Modes of Action Using Live-Cell FTIR Spectroscopy

机译:使用活细胞FTIR光谱法鉴定在不同作用方式的抗癌药物中处理的雌激素受体表达的MCF7细胞的反应

获取原文
           

摘要

Recently, we have shown that changes in Fourier transform infrared (FTIR) spectra of living MDA-MB-231 cells (a triple negative cell line) upon exposure to anticancer drugs reflect the changes in the cellular compositions which are correlated to the modes of action of drugs. In the present study, MCF7 cells (an estrogen receptor expressing breast cancer cell line) were exposed to three anticancer drugs belonging to two well-characterized anticancer classes: selective estrogen receptor modulators (SERMs) and DNA-intercalating agent. First, we evaluated if the changes in the spectrum of cells are according to the modes of action of drugs and the characteristics of the MCF7 cell line in the same way as the MDA-MB-231 cell. Living MCF7 cells were treated in the three drugs at half maximal inhibitory concentration (IC50), and the difference spectra were analyzed using principal component analysis (PCA). The results demonstrated clear separation between tamoxifen/toremifene (SERM)-treated cells from the doxorubicin (DNA-intercalator)-treated and untreated cells (control). Tamoxifen and toremifene induced similar spectral changes in the cellular compositions of MCF7 cells and lead to the clustering of these two drugs in the same quadrant of the principal component 1 (PC1) versus PC2 score plots. The separation is mostly attributed to their similar modes of actions. However, doxorubicin-treated MCF7 cells highlighted spectral changes that mainly occur in bands at 1085 and 1200–1240 cm~(–1), which could be associated with the DNA-intercalation effects of the drug. Second, the pairwise PCA at various individual time points was employed to investigate whether the spectral changes of MCF7 and MDA-MB-231 cells in response to the IC50 of tamoxifen/toremifene and doxorubicin are dependent on the characteristics of the cell lines. The estrogen-expressing MCF7 cells demonstrated significant differences in response to the SERMs in comparison to the triple negative MDA-MB-231 cells, suggesting that different modes of action have taken place in the two tested cell lines. In contrast, the doxorubicin-treated MDA-MB-231 and MCF7 cells show similar changes in 1150–950 cm~(–1), which indicates that the DNA intercalation effect of doxorubicin is found in both cell lines. The results have demonstrated that live-cell FTIR analysis is sensitive to the different modes of action from the same drugs on cells with different characteristics.
机译:最近,我们已经表明,在暴露于抗癌药物时,在暴露于抗癌药物后,活性MDA-MB-231细胞(三重阴性细胞系)的傅里叶变换红外(FTIR)光谱的变化反映了与作用方式相关的细胞组合物的变化药物。在本研究中,MCF7细胞(表达乳腺癌细胞系的雌激素受体)暴露于属于两个特征抗癌的三种抗癌药物:选择性雌激素受体调节剂(SERMS)和DNA嵌入剂。首先,如果细胞光谱的变化根据药物的作用方式和MCF7细胞系的特性以与MDA-MB-231细胞相同的方式,则评估。将活性MCF7细胞在三种药物中处理半最大抑制浓度(IC50),并使用主成分分析(PCA)分析差异光谱。结果表明,来自多柔比蛋白(DNA - 嵌入剂) - 治疗和未处理的细胞(对照)之间的Tamoxifen / Toremifene(Serm)-treated细胞之间的清晰分离。 Tamoxifen和Toremifene诱导MCF7细胞的细胞组合物的相似的光谱变化,并导致这两种药物在主成分1(PC1)的相同象限中与PC2得分图中的聚类。分离主要归因于它们类似的动作模式。然而,多柔比蛋白处理的MCF7细胞突出显示的光谱变化,主要发生在1085和1200-1240cm〜(-1)的条带中,这可能与药物的DNA嵌入效应相关。其次,采用各个单位点的成对PCA研究MCF7和MDA-MB-231细胞的光谱变化是否响应于Tamoxifen / Toremifene和多柔比蛋白的IC 50是取决于细胞系的特征。与三重阴性MDA-MB-231细胞相比,表达雌激素的MCF7细胞响应于SERMS的响应而表现出显着差异,表明两种测试的细胞系中已经发生了不同的作用方式。相反,多柔比蛋白处理的MDA-MB-231和MCF7细胞显示出1150-950cm〜(-1)的类似变化,这表明在两种细胞系中发现了多柔比星的DNA嵌入效果。结果表明,活细胞FTIR分析对具有不同特征的相同药物的不同作用方式敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号